Skip to content

Hemodiafiltration In Acute Liver Failure

Randomized Trial Of Effect Of Hemodiafiltration On Mortality In Acute Liver Failure At 30 Days: A Pilot Study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/04/018433
Enrollment
14
Registered
2019-04-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K720- Acute and subacute hepatic failure

Interventions

Intervention1: Hemodiafiltration: Hemodiafiltration increases the clearence of the large toxins by large volume ultrafiltrtion. Ultrafiltration carries toxins through the membrane pores by fluid flow,

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria also has serum ammonia levels of greater than or equal to 150 micromoles per liter.

Exclusion criteria

Exclusion criteria: Age less than 18 years or more than 65 years. serum ammonia levels less than 150 micromoles per liter. Preexisting diagnosis or suspicion of chronic kidney disease. Preexisting diagnosis or suspicion of chronic liver disease. Preexisting diagnosis of bleeding diathesis. Pregnancy or Lactation. Presence of AKI stage 3 (as per KDIGO AKI staging). Presence of past diagnosis of malignancy. Anticipated need for dialysis within next 12 hours as judged by the treating team. Systolic blood pressure Requiring artificial ventilation.

Design outcomes

Primary

MeasureTime frame
Percentage of subjects in either group who are alive at 30 days after enrollment.Timepoint: 30 days after enrollment.

Secondary

MeasureTime frame
1.Percentage of subjects who develop new onset respiratory failure requiring mechanical ventilation. 2.Percentage of subjects who develop refractory shock. 3.Percentage of subjects who develop new onset major bleeding complications. 4.Percentage of subjects who develop new onset sepsis or any infectious complications. 5.Percentage of subjects in either group who are alive at 3,7 and 14 days after enrollment. 6.Time to mortality.Timepoint: At the time of enrollment. At days 3,7, 14 and 30 days after enrollment.

Countries

India

Contacts

Public Contactvuppada siddhartha

Postgraduate Institute of Medical Education and Research (PGIMER)

kohlihs2009@gmail.com9417525285

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026